Información de la revista
Vol. 16. Núm. 5. P2.
Páginas 433-434 (Septiembre - Octubre 2020)
Descargar PDF
Más opciones de artículo
Vol. 16. Núm. 5. P2.
Páginas 433-434 (Septiembre - Octubre 2020)
Letter to the Editor
Acceso a texto completo
Comment on “Clinical practice guidelines for the treatment of systemic lupus erythematosus by the Mexican College of Rheumatology”
Comentario sobre “Guía de práctica clínica para el manejo del lupus eritematoso sistémico propuesta por el Colegio Mexicano de Reumatología”
Juan Manuel Mejia-Vilet
Autor para correspondencia
, Javier Tejeda-Maldonado, Ricardo Correa-Rotter
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Nefrología y Metabolismo Mineral, Vasco de Quiroga No. 15, Belisario Domínguez Sección XVI, Mexico City, Mexico
Contenido relaccionado
Reumatol Clin. 2020;16:434-510.1016/j.reuma.2018.11.012
Leonor A. Barile-Fabris, Lilia Andrade Ortega, Daniel Xibillé Friedmman
Este artículo ha recibido
Información del artículo
Texto completo
Descargar PDF
Tablas (1)
Table 1. Studies comparing hemodialysis (HD) and peritoneal dialysis (PD) modalities in systemic lupus erythematosus patients on end-stage renal disease.
Texto completo
Dear editor:

We read with high respect the recent publication of the Mexican Clinical Practice guidelines for the management of systemic lupus erythematosus (SLE).1 This is a much-needed reference for Mexico, a country with a high number of SLE patients. From the nephrologist perspective, lupus nephritis (LN) is also of great concern to Latin America given the high percentage of LN observed in recent renal biopsy registries from the region.2 It is known that LN affects 40–60% of patients with SLE and 10–20% will progress to end-stage renal disease within 10 years of diagnosis. These patients will receive some sort of renal replacement therapy (RRT): peritoneal dialysis (PD), hemodialysis (HD) or renal transplantation.3

In the LN management section, these new recommendations suggest “hemodialysis (HD) as the first option of renal replacement treatment in patients with chronic kidney disease (CKD) due to LN, given that peritoneal dialysis (PD) is associated with a higher number of complications and mortality due to immunosuppression (quality of evidence: moderate, strong recommendation)”.

Studies in the nephrology community comparing patient survival on hemodialysis versus peritoneal dialysis in patients with end-stage renal disease from several etiologies have yielded conflicting results. Some underlying reasons encompass the differences in the included populations (e.g. incident vs. prevalent, diabetic vs. non-diabetic), differences in the methodology used (e.g. intention to treat vs. received dialysis modality) and importantly, the unavailability of complete information of important confounders (presence or severity of comorbidities, residual kidney function, administered dialysis dose, among others). Researchers have tried to overcome these difficulties with the use of multivariate modeling, multilevel modeling or the use of propensity scores. However, confounding remains a threat to validity of most studies.

The recommendation in these new guidelines is based on the study by Weng et al. from Taiwan.4 This is a small observational report that found a higher number of infections and death among 24 SLE patients undergoing PD as compared to 12 SLE patients on HD. The study has multiple methodological limitations, the most notable being the absence of correction for the baseline differences with any of the aforementioned statistical techniques. Some other important limitations are mentioned in the manuscript's discussion, for example, the health system in Taiwan did not cover erythropoietin stimulating agents (ESAs) for PD patients as it did for the HD group. Several other studies have been performed to define the best dialytic modality for SLE patients, some of them with similar methodological limitations (Table 1).

Table 1.

Studies comparing hemodialysis (HD) and peritoneal dialysis (PD) modalities in systemic lupus erythematosus patients on end-stage renal disease.

StudyCountryFollow-up (months)PatientsInfectious eventsSurvivalAdjustment for baseline differences
HD  PD  HD  PD  HD (%)  PD (%) 
Nossent6 1990  Holland  60  32  23  Not reported92  80  No 
Goo7 2004  Korea  53±29  21  11  Not reportedNo differenceNo 
Weng4 2009  Taiwan  37 (PD)/127 (HD)  12  24  0.10 episodes/pt/year  0.36 episodes/pt/year  92  75  No 
Kang8 2011  Korea  60±36  28  14  0.64 episodes/pt/year  0.36 episodes/pt/year  79  93  Yes 
Chang9 2013  Taiwan  Unknown  813  260  Infections leading to death9.1%  Infections leading to death 6.9%  79  87  Yes 
Contreras5 2014  USA  36  1352  1352  Not reported79  78  Yes 
Levy10 2015  France  23  308  60  Not reported83  82  Yes 

HD, hemodialysis; PD, peritoneal dialysis; episodes/pt/year, infectious episodes per patient per year (current recommendation is <0.6 dialysis related episodes/patient/year for peritoneal dialysis).

The largest study to date that compared PD vs. HD in SLE patients was performed by Contreras et al.5 with data from the US Renal Data System. In this study, 1352 SLE patients with PD were matched with a propensity score approach to 1352 SLE patients with HD. There was a similar 3-year mortality between both modalities (21.4% vs. 22.5%), with similar cardiovascular (10.5% vs. 9.5%) and infection-related mortality (3.0% vs. 4.4%). These results were not modified in a sensitivity analysis in the unmatched population by a Cox-regression analysis that included all the appropriate predictors.

Therefore, we believe there is not enough evidence to support the preference for HD over PD in SLE patients. Renal replacement therapy selection in most CKD patients requires a case-by-case evaluation by the healthcare team keeping in mind the patient preferences. It is clear that an effort should be made to transplant these patients as soon as possible due to the lower mortality achieved with renal transplantation.

D. Xibillé-Friedmann, M. Pérez-Rodríguez, S. Carrillo-Vázquez, et al.
Guía de práctica clínica para el manejo del lupus eritematoso sistémico propuesta por el Colegio.
Mexicano de Reumatología Reumatol Clínica, (2018),
M.M. O'Shaughnessy, S.L. Hogan, B.D. Thompson, et al.
Glomerular disease frequencies by race, sex and region: results from the International Kidney Biopsy Survey.
Nephrol Dial Transplant, 33 (2018), pp. 661-669
M.G. Tektonidou, A. Dasgupta, M.M. Ward.
Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015 a systematic review and bayesian meta-analysis.
Arthritis Rheumatol, 68 (2016), pp. 1432-1441
C.-H. Weng, C.W. Hsu, C.C. Yu, et al.
Peritoneal dialysis and hemodialysis in systemic lupus erythematosus patients: comparison of clinical outcomes.
Kidney Blood Press Res, 32 (2009), pp. 451-456
G. Contreras, J. Pagan, R. Chokshi, et al.
Comparison of mortality of ESRD patients with lupus by initial dialysis modality.
Clin J Am Soc Nephrol, 9 (2014), pp. 1949-1956
H.C. Nossent, T.J. Swaak, J.H. Berden.
Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis Dutch Working Party on SLE.
Am J Med, 89 (1990), pp. 169-174
Y.S. Goo, H.C. Park, H.Y. Choi, et al.
The evolution of lupus activity among patients with end-stage renal disease secondary to lupus nephritis.
Yonsei Med J, 45 (2004), pp. 199-206
S.H. Kang, B.H. Chung, S.R. Choi, et al.
Comparison of clinical outcomes by different renal replacement therapy in patients with end-stage renal disease secondary to lupus nephritis.
Korean J Intern Med, 26 (2011), pp. 60-67
Y.S. Chang, C.J. Liu, T.H. Wu, et al.
Survival analysis in systemic lupus erythematosus patients on maintenance dialysis: a nationwide population-based study in Taiwan.
Rheumatology, 52 (2013), pp. 166-172
B. Levy, C. Couchoud, J.P. Rougier, N. Jourde-Chiche, E. Daugas.
Outcome of patients with systemic lupus erythematosus on chronic dialysis: an observational study of incident patients of the French National Registry 2002–2012.
Lupus, 24 (2015), pp. 1111-1121
Copyright © 2018. Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología
Reumatología Clínica
Opciones de artículo
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?